Palisade Bio Successfully Demonstrates PALI-2108 Bioactivation
DENVER, Colo., Apr 16, 2024 (247marketnews.com)- Palisade Bio, Inc. (Nasdaq:PALI) stated that it successfully completed its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, demonstrating that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
“The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,” stated Dr. Mitch Jones, Palisade Bio’s CMO. “The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as an innovative therapeutic approach for managing UC.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (PALI)
- Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
- Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
- 24/7 Market News Snapshot 07 August, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/23/25 09:00 AM
- Today’s Top Performers: MoBot’s Market Review 07/21/25 05:00 PM